Drugmakers Moderna and AstraZeneca are partnering up to develop a “mRNA therapeutic” to treat life-threatening cardiovascular disease such as heart failure. “We are collaborating with @AstraZeneca on an mRNA therapeutic (AZD8601) that encodes for VEGF-A to promote recovery of cardiac function through tissue regeneration,” Moderna said in a Twitter post Thursday. The biotechnology company included a link to a phase two study dated Nov. 15, 2021, that analyzed messenger RNA treatment in patients undergoing coronary artery bypass grafting surgery. That study produced “positive” results, Moderna said. Moderna said the findings were presented at the American Heart Association’s Scientific Sessions 2021 annual meeting in Boston. The treatment aims to promote the growth of new blood vessels, and therefore heal the hearts of surgery patients, the Philadelphia Inquirer reported. The study of 11 patients saw seven treated with the “mRNA therapeutic” and four receive placebo injections. All seven recipients who received the …